Alto Neuroscience (ANRO) highlighted the publication of data from the PAX-D study in The Lancet Psychiatry, evaluating pramipexole in patients with treatment-resistant depression. The study, funded by the U.K. government, showed pramipexole augmentation demonstrated a large reduction in symptoms relative to placebo at 12 weeks but had a high rate of adverse effects. The study results guided Alto’s acquisition of ALTO-207, a fixed-dose combination of pramipexole and ondansetron designed to mitigate dose-limiting adverse events. Alto plans to initiate a potentially pivotal Phase 2b trial for ALTO-207 by mid-2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANRO:
- Optimistic Buy Rating for Alto Neuroscience Amid Promising ALTO-203 Developments and Strategic Opportunities
- Promising Phase 2 Results for ALTO-203 in Treating Anhedonia-MDD Justify Buy Rating
- Alto Neuroscience identifies biomarker, reports ALTO-203 pharmacodynamic results
- Alto Neuroscience Reports Positive Phase 2 Trial Results
- Promising Future for Alto Neuroscience: Strategic Acquisition and Strong Financial Position Drive Buy Rating